GeoVax Labs, Inc. — fact timeline

GeoVax Labs, Inc. shareholders approved Advisory Vote on the Frequency of Future Advisory Votes on the Compensation of our Named Executive Officers at the 2026-06-17 meeting.

“Advisory Vote on the Frequency of Future Advisory Votes on the Compensation of our Named Executive Officers Our stockholders approved, on an advisory basis, the frequency of future advisory votes on the compensation of our Named Executive Officers (as defined in the Proxy Statement). The determination was to hold such advisory votes on a three-year cycle. 1 Year 2 Years 3 Years Abstain 339,064 24,463 97,058 18,033”

GeoVax Labs, Inc. shareholders approved Advisory Vote on the Compensation of our Named Executive Officers at the 2026-06-17 meeting.

“Advisory Vote on the Compensation of our Named Executive Officers Our stockholders approved, on an advisory basis, the compensation of our Named Executive Officers (as defined in the Proxy Statement). There were a total of 810,066 broker non-votes on this item. For Against Abstain 385,843 65,826 26,949”

GeoVax Labs, Inc. shareholders approved Ratification of Independent Auditor at the 2026-06-17 meeting.

“Ratification of Independent Auditor Our stockholders approved the ratification of Wipfli LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. There were no broker non-votes on this item. For Against Abstain 1,185,525 37,409 65,750”

GeoVax Labs, Inc. shareholders approved Approval of the May 2026 Warrant Exercise Proposal at the 2026-06-17 meeting.

“Approval of the May 2026 Warrant Exercise Proposal Our stockholders approved a proposal to approve, pursuant to Nasdaq listing rules, the issuance of up to 1,702,986 shares of our common stock upon exercise of common stock purchase warrants issued to certain institutional investors in connect with the warrant exercise inducement which occurred on May 7, 2026. There were a total of 810,066 broker non-votes on this item. For Against Abstain 375,831 35,336 67,451”

GeoVax Labs, Inc. shareholders approved Approval of the March 2026 Warrant Exercise Proposal at the 2026-06-17 meeting.

“Approval of the March 2026 Warrant Exercise Proposal Our stockholders approved a proposal to approve, pursuant to Nasdaq listing rules, the issuance of up to 1,269,316 shares of our common stock upon exercise of common stock purchase warrants issued to certain institutional investors in connect with the warrant exercise inducement which occurred on March 31, 2026. There were a total of 810,066 broker non-votes on this item. For Against Abstain 395,365 66,838 16,415”

GeoVax Labs, Inc. shareholders approved Approval of the February 2026 Warrant Exercise Proposal at the 2026-06-17 meeting.

“Approval of the February 2026 Warrant Exercise Proposal Our stockholders approved a proposal to approve, pursuant to Nasdaq listing rules, the issuance of up to 865,804 shares of our common stock upon exercise of common stock purchase warrants issued to certain institutional investors in connect with the private placement offering which occurred on February 17, 2026. There were a total of 810,066 broker non-votes on this item. For Against Abstain 395,198 65,103 18,317”

GeoVax Labs, Inc. shareholders approved Election of Directors at the 2026-06-17 meeting.

“Election of Directors Our stockholders voted to elect the slate of directors consisting of seven members to hold office until the next annual meeting of stockholders or until their successors are duly elected and qualified. There were a total of 810,066 broker non-votes on this item. Nominee ​ For ​ ​ Withheld ​ Randal D. Chase ​ ​ 420,305 ​ ​ ​ 58,313 ​ David A. Dodd ​ ​ 418,963 ​ ​ ​ 59,655 ​ Dean G. Kollintzas ​ ​ 420,198 ​ ​ ​ 58,420 ​ Nicole Lemerond ​ ​ 417,920 ​ ​ ​ 61,426 ​ Robert T. McNally ​ ​ 419,481 ​ ​ ​ 59,137 ​ Jayne Morgan ​ ​ 420,422 ​ ​ ​ 58,196 ​ John N. Spencer, Jr. ​ ​ 420,434 ​ ​ ​ 58,184 ​”

GeoVax Labs, Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners (the “Placement Agent”) (effective 2026-05-18).

“A.G.P./Alliance Global Partners (the “Placement Agent”) acted as the exclusive placement agent in connection with the Offering under a Placement Agency Agreement, dated as of May 18, 2026 (the “Placement Agency Agreement”) between the Company and the Placement Agent.”

GeoVax Labs, Inc. entered into Purchase Agreement with the purchasers party thereto (effective 2026-05-18).

“On May 18, 2026, GeoVax Labs, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers party thereto, pursuant to which the Company agreed to issue and sell, in an unregistered private placement (the “Offering”), (i) pre-funded warrants”

GeoVax Labs, Inc. reported the quarter ended March 31, 2026 results: net income $5.3 million.

“Net loss for the three months ended March 31, 2026, was $5.3 million”

GeoVax Labs, Inc. issued an aggregate of up to 1,002,288 shares of the Company’s common stock of warrant to Holders of existing warrants for for their agreement to exercise for cash their Exercised Warrants to purchase an aggregate of 501,144 shares.

“with the September 2025 Warrants, the “Exercised Warrants”), pursuant to which the Holders agreed to exercise for cash their Exercised Warrants to purchase an aggregate of 501,144 shares of the Company’s common stock in consideration for the Company’s agreement to issue new warrants (the “New Warrants”) to purchase an aggregate of up to 1,002,288 shares of”

GeoVax Labs, Inc. entered into Inducement Letters with holders of existing warrants valued at aggregate gross proceeds of approximately $595,000 (effective 2026-05-07).

“On May 7, 2026, GeoVax Labs Inc. (the “Company”), entered into common stock warrant exercise inducement offer letters (the “Inducement Letters”) with holders (the “Holders”) of existing warrants to purchase shares of the Company’s common stock”

GeoVax Labs, Inc. reported the year ended December 31, 2025 results: revenue $2.5 million, net income $21.5 million, EPS $22.40 per share.

“Net loss for the year ended December 31, 2025, was $21.5 million, or $22.40 per share, as compared to $25.0 million, or $120.46 per share, for the year ended December 31, 2024. Revenue : For the year ended December 31, 2025, the Company reported $2.5 million of government contract revenues associated with the BARDA/RRPV Project NextGen award, compared to $4.0 million during 2024.”

GeoVax Labs, Inc. issued an aggregate of up to 1,269,316 shares of the Company's common stock of warrant to Holders of Existing Warrants for exercise of Existing Warrants for cash at $1.36 per share, aggregate gross proceeds of approximately $863,000.

“which the Holders agreed to exercise for cash their Existing Warrants to purchase an aggregate of 634,658 shares of the Company’s common stock, at a reduced exercised price of $1.36 per share, in consideration for the Company’s agreement to issue new warrants (the “New Warrants”) to purchase an aggregate of up to 1,269,316 shares of the Company’s common stock”

GeoVax Labs, Inc. issued 402,000 shares of common stock of common stock to institutional investors for public offering price of $2.31 per share, net proceeds approximately $865,000.

“purchase an aggregate of 432,902 shares of Common Stock (such shares issuable upon exercise of the Common Warrants, the “Common Warrant Shares”). The public offering price was $2.31 for each Share and $2.30999 per Pre-Funded Warrant. The Pre-Funded Warrants have an exercise price of $0.00001 per share, are exercisable immediately and may be exercised at any”

GeoVax Labs, Inc. entered into Purchase Agreement with the purchasers party thereto valued at approximately $865,000 (effective 2026-02-13).

“On February 13, 2026, GeoVax Labs, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers party thereto, pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Offering”), an aggregate of (i) 402,000 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 30,902 shares of Common Stock (the “Pre-Funded Warrant Shares”).”

GeoVax Labs, Inc.: Filed Certificate of Amendment for 1-for-25 reverse stock split (effective 2026-01-09).

“On January 9, 2026, GeoVax Labs, Inc. (the “Company” or “we”) filed a Certificate of Amendment to our Certificate of Incorporation effecting a 1-for-25 reverse stock split”

GeoVax Labs, Inc. entered into Placement Agency Agreement with Roth Capital Partners, LLC (effective 2025-12-19).

“On December 19, 2025, GeoVax Labs, Inc. (the “Company”) entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”)”

GeoVax Labs, Inc. entered into Purchase Agreement with the purchasers party thereto valued at aggregate of 13,244,896 common units (effective 2025-12-19).

“On December 19, 2025, GeoVax Labs, Inc. (the “Company”) entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with the purchasers party thereto, pursuant to which the Company agreed to issue and sell, in a public offering (the “Offering”), an aggregate of 13,244,896 common units”

GeoVax Labs, Inc. issued 11,904,768 shares of Common Stock of warrant.

“In a concurrent private placement, the Company offered common warrants to the purchasers, with each warrant exercisable to purchase one share of Common Stock (the “Common Warrants”), with three Common Warrant to accompany each share of Common Stock sold in the Offering, and to purchase in the aggregate of 11,904,768 shares of Common Stock (the “Common Warrant Shares”).”

GeoVax Labs, Inc. issued 3,968,256 shares of common stock for $0.63 per Share.

“share of Common Stock sold in the Offering, and to purchase in the aggregate of 11,904,768 shares of Common Stock (the “Common Warrant Shares”). The public offering price was $0.63 for each Share coupled with the Common Warrants. The Common Warrants have an exercise price of $0.63 per share. Under the terms of the Purchase Agreement and to comply with Nasdaq”

GeoVax Labs, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“July 31, 2025, the “Company received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the preceding 30 consecutive business days, the closing bid price for the Company’s common stock was below the minimum $1.00 per share requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). In accordance with Nasdaq rules, the Company has been provided an initial period of 180 calendar days, or until January 27, 2026 (the “Compliance Date”), to”

GeoVax Labs, Inc. reported financial results for first quarter ended March 31, 2024.

“On May 14, 2024, GeoVax Labs, Inc. (the “Company”) issued a press release reporting its results of operations for the quarter ended March 31, 2024.”

GeoVax Labs, Inc. reported financial results for the year ended December 31, 2023.

“On February 29, 2024, GeoVax Labs, Inc. (the “Company”) issued a press release reporting its results of operations for the year ended December 31, 2023.”

GeoVax Labs, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

“February 16, 2024, the Company received a letter from Nasdaq stating that Nasdaq has determined the Company to have regained compliance with The Nasdaq Capital Market listing requirements and that, consequently, the scheduled Hearing has been cancelled. The Company’s securities will continue to be listed and traded on The Nasdaq Stock Market.”

GeoVax Labs, Inc.: Filed Certificate of Amendment to Certificate of Incorporation to effect a 1-for-15 reverse stock split and reduce authorized shares of common stock from 600,000,000 to 150,000,000 (effective 2024-01-30).

“On January 30, 2024, GeoVax Labs, Inc. (the “Company” or “we”) filed a Certificate of Amendment to our Certificate of Incorporation effecting a 1-for-15 reverse stock split pursuant to which each fifteen (15) shares of the Company’s Common Stock, par value $0.001 per share (“Old Common Stock”), issued and outstanding immediately prior to the filing automatically and without any action on the part of the respective holders thereof, was combined and reclassified into one (1) share of Common Stock, par value $0.001 per share (the “New Common Stock”) (and such combination and conversion, the “Reverse Stock Split”).”

GeoVax Labs, Inc. shareholders approved Amendment to Certificate of Incorporation to effect a reverse stock split of issued and outstanding common stock at a ratio of not less than 1-for-5 and not greater than 1-for-15, such ratio to be determined by the Board of Directors at any time prior to January 31, 2024 at the 2024-01-16 meeting.

“Reverse Stock Split Our stockholders approved an amendment to our Certificate of Incorporation to effect a reverse stock split of our issued and outstanding common stock at a ratio of not less than 1-for-5 and not greater than 1-for-15, such ratio to be determined by our Board of Directors, at any time prior to January 31, 2024. There were no broker non-votes on this item. For Against Abstain 9,895,182 3,589,641 339,521”

GeoVax Labs, Inc. shareholders approved Amendment to Certificate of Incorporation to reduce authorized shares of common stock from 600,000,000 to 150,000,000 at the 2024-01-16 meeting.

“Reduction in Authorized Shares Our stockholders approved an amendment to our Certificate of Incorporation to reduce our authorized shares of common stock, $0.001 par value, from 600,000,000 to 150,000,000. There were no broker non-votes on this item. For Against Abstain 11,195,568 2,370,399 258,377”

GeoVax Labs, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“December 6, 2023, the Company received a notice (the “Notice”) from The Nasdaq Stock Market, LLC ("Nasdaq") stating that Nasdaq has determined to delist the Company's securities from the Nasdaq Capital Market for failure to maintain a minimum bid price of $1.00 per share in accordance with Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). The Company intends to appeal the Nasdaq determination by requesting a hearing (the "Hearing") before a Nasdaq Hearings Panel (the "Panel") to seek continued listing pending its return to compliance with the Bid Price Requirement. The Hearing requ”

GeoVax Labs, Inc. reported financial results for the third quarter ended September 30, 2023.

“On November 8, 2023, GeoVax Labs, Inc. (the “Company”) issued a press release reporting its results of operations for the quarter ended September 30, 2023.”

GeoVax Labs, Inc. reported financial results for the quarter ended June 30, 2023.

“GeoVax Labs, Inc. (the “Company”) issued a press release reporting its results of operations for the quarter ended June 30, 2023.”

GeoVax Labs, Inc. shareholders approved Advisory Vote on the Frequency of Future Advisory Votes on the Compensation of our Named Executive Officers at the 2023-08-01 meeting.

“Advisory Vote on the Frequency of Future Advisory Votes on the Compensation of our Named Executive Officers Our stockholders approved, on an advisory basis, the frequency of future advisory votes on the compensation of our Named Executive Officers (as defined in the Proxy Statement). The determination was to hold such advisory votes on a three-year cycle.”

GeoVax Labs, Inc. shareholders approved Advisory Vote on the Compensation of our Named Executive Officers at the 2023-08-01 meeting.

“Advisory Vote on the Compensation of our Named Executive Officers Our stockholders approved, on an advisory basis, the compensation of our Named Executive Officers (as defined in the Proxy Statement).”

GeoVax Labs, Inc. shareholders approved Approval of the GeoVax Labs, Inc. 2023 Stock Incentive Plan at the 2023-08-01 meeting.

“Approval of the GeoVax Labs, Inc. 2023 Stock Incentive Plan Our stockholders approved the GeoVax Labs, Inc. 2023 Stock Incentive Plan.”

GeoVax Labs, Inc. shareholders approved Increase in Shares Subject to the GeoVax Labs, Inc. 2020 Stock Incentive Plan at the 2023-08-01 meeting.

“Increase in Shares Subject to the GeoVax Labs, Inc. 2020 Stock Incentive Plan Our stockholders approved an increase in the aggregate number of shares of common stock subject to the GeoVax Labs, Inc. 2020 Stock Incentive Plan from 1,500,000 shares to 2,250,000 shares.”

GeoVax Labs, Inc. shareholders approved Ratification of Independent Auditor at the 2023-08-01 meeting.

“Ratification of Independent Auditor Our stockholders approved the ratification of Wipfli LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.”

GeoVax Labs, Inc. shareholders approved Election of Directors at the 2023-08-01 meeting.

“Election of Directors Our stockholders voted to elect the slate of directors consisting of seven members to hold office until the next annual meeting of stockholders or until their successors are duly elected and qualified. There were a total of 7,216,927 broker non-votes on this item.”

GeoVax Labs, Inc. entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC valued at up to $6,529,000 (effective 2023-07-18).

“On July 18, 2023, GeoVax Labs, Inc. (the “Company”) entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), as sales agent, pursuant to which we may offer and sell, from time to time, through Wainwright shares of our common stock, $0.001 par value per share.”

GeoVax Labs, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“June 8, 2023, the Company received written notification from Nasdaq granting the Company’s request. The Company now has until December 4, 2023 to meet the Bid Price Requirement (the “Compliance Date”). The grant of the extension by Nasdaq has no effect on the listing of the Company’s shares, which will continue to be listed on the Nasdaq Capital Market under the symbol “GOVX.” If at any time prior to the Compliance Date, the bid price of the Company's common stock closes at, or above, $1.00 per share for a minimum of ten (10) consecutive business days Nasdaq will provide the Company with writt”

GeoVax Labs, Inc. reported three months ended March 31, 2023 results: net income $4,037,916, EPS $0.15 per share.

“Net Loss : Net loss for the three months ended March 31, 2023, was $4,037,916, or $0.15 per share”

GeoVax Labs, Inc. reported financial results for the year ended December 31, 2022.

“On March 23, 2023, GeoVax Labs, Inc. (the “Company”) issued a press release reporting its results of operations for the year ended December 31, 2022.”

GeoVax Labs, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“December 9, 2022, the “Company received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the preceding 30 consecutive business days, the closing bid price for the Company’s common stock was below the minimum $1.00 per share requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). In accordance with Nasdaq rules, the Company has been provided an initial period of 180 calendar days, or until June 7, 2023 (the “Compliance Date”), to”

Jayne Morgan, M.D. was appointed as Director at GeoVax Labs, Inc..

“On December 7, 2022, our Board of Directors (the “Board”) appointed Jayne Morgan, M.D. to the Board, effective as of December 7, 2022.”

GeoVax Labs, Inc. reported financial results for the third quarter ended September 30, 2022.

“On November 9, 2022, GeoVax Labs, Inc. (the “Company”) issued a press release reporting its results of operations for the quarter ended September 30, 2022.”

Nicole Lemerond was appointed as Director at GeoVax Labs, Inc..

“On August 31, 2022, our Board of Directors (the “Board”) appointed Nicole Lemerond to the Board, effective as of August 31, 2022.”